Showing 1211-1220 of 1414 results for "".
- MacuLogix Reaches Milestone with One Million Dark Adaptation Testshttps://modernod.com/news/maculogix-reaches-milestone-with-one-million-dark-adaptation-tests/2480853/MacuLogix announced that more than 1 million dark adaptation tests have been performed using either the company’s original AdaptDx or the head-mounted AdaptDx Pro guided by Theia. Both devices use the same proprietary technology to efficiently measure dark adaptatio
- TearLab Announces Adam Szaronos as President and CEO, and Jim Mazzo as Executive Chairman of the Boardhttps://modernod.com/news/tearlab-announces-adam-szaronos-as-president-and-ceo-and-jim-mazzo-as-executive-chairman-of-the-board/2480506/TearLab announced that Adam Szaronos has been appointed President and Chief Executive Officer by the company's Board of Dir
- Oyster Point Pharma Announces Collaboration with Adaptive Phage Therapeutics to Target Ophthalmic Diseaseshttps://modernod.com/news/oyster-point-pharma-announces-collaboration-with-adaptive-phage-therapeutics-to-target-ophthalmic-diseases/2479281/Oyster Point Pharma announced a newly formed research collaboration with Adaptive Phage Therapeutics (APT) to leverage APT’s PhageBank technology for the development of potential treatments for multiple ophthalmic diseases. APT’s PhageBank technology is engi
- Tilak Healthcare Launches US Pilot for OdySight Medical Vision Monitoring Apphttps://modernod.com/news/tilak-healthcare-launches-us-pilot-for-odysight-medical-vision-monitoring-app/2479202/Tilak Healthcare is launching a pilot program in the US with Novartis for OdySight, Tilak’s first clinically tested mobile app for patient remote vision monitoring. The program is the first to launch under an international collaboration announced in 2020 between Tilak Healthcare and
- AdaptDx Pro’s On-Board AI Technician Now Speaks in Multiple Languageshttps://modernod.com/news/adaptdx-pros-on-board-ai-technician-now-speaks-in-multiple-languages/2479039/MacuLogix announced its first major software upgrade for its AdaptDx Pro portable dark adaptometer. Once the software is automatically downloaded and installed, the artificial intelligence-driven onboard technician, T
- Tilak Healthcare Partners With Novartis to Promote Mobile App OdySighthttps://modernod.com/news/tilak-healthcare-partners-with-novartis-in-ophthalmology/2478634/Tilak Healthcare, a provider of digital therapeutics, has announced an agreement with Novartis Pharma for the promotion internationally of OdySight, Tilak Healthcare’s first clinically validated mobile app for patient remote vision monitoring. Financial terms of the deal were not disclosed
- Adaptilens Announces $1.6 Million in Seed Funding for Development of Accommodating IOLhttps://modernod.com/news/adaptilens-announces-1-6-million-in-seed-funding-for-development-of-accommodating-iol/2478536/Adaptilens announced a $1.6 million seed funding to fund the company’s development of an innovative accommodating IOL with the aim of allowing patients to live their lives free of glasses and contact lenses. The funding was led by Pillar VC with additional participat
- Nicox Selects 0.1% NCX 470 Dose in Adaptive Stage of Mont Blanc Phase 3 Glaucoma Trialhttps://modernod.com/news/nicox-selects-0-1-ncx-470-dose-in-adaptive-stage-of-mont-blanc-phase-3-glaucoma-trial/2478316/Nicox SA announced the selection of the 0.1% dose of NCX 470 for phase 3 following the completion of the adaptive portion of the Mont Blanc phase 3 clinical trial. As is customary for adaptive design trials, in order to maintain the integrity of the trial, no data from the adaptive portion of the
- Nicox Completes Enrollment of the Adaptive Design Cohort of NCX 470 Mont Blanc Phase 3 Glaucoma Trialhttps://modernod.com/news/nicox-completes-enrollment-of-the-adaptive-design-cohort-of-ncx-470-mont-blanc-phase-3-glaucoma-trial/2478234/Nicox SA announced that it completed enrollment of the adaptive design patient cohort in its multicenter Mont Blanc phase 3 trial, evaluating NCX 470 ophthalmic solution vs. latanoprost ophthalmic solution 0.005% for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.
- TearLab Appoints Adam Szaronos as Chief Commercial Officerhttps://modernod.com/news/tearlab-appoints-adam-szaronos-as-chief-commercial-officer/2478094/TearLab announced the appointment of Adam Szaronos to the position of Chief Commercial Officer (CCO). Mr. Szaronos brings a wealth of experience gained over the past 15 years and will help guide the evolution of TearLab as it